Åslaug Helland

Professor II - Forskningsleder KRE
Image of Åslaug Helland
Norwegian version of this page
Username
Visiting address Forskningsveien 2 A OUS Rikshospitalet 0372 Oslo
Postal address Postboks 4950 Nydalen OUS, Rikshospitalet 0424 Oslo

Publications

  • Helland, Åslaug; Steinskog, Eli Sihn Samdal; Blix, Egil St⊘re; Flobak, Åsmund; Brabrand, Sigmund & Puco, Katarina [Show all 20 contributors for this article] (2024). Hever kvaliteten på behandling av kreft. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 144(1), p. 1–5. doi: 10.4045/tidsskr.23.0740.
  • Helland, Åslaug; Myklebust, Tor Åge; Conte, Simona; Frederiksen, Line Elmerdahl; Aarøe, Jørgen Mømb & Enerly, Espen (2023). EGFR-mutation testing, treatment patterns and clinical outcomes in patients with stage IB–IIIA non-small cell lung cancer in Norway–a nationwide cohort study. Cancer Treatment and Research Communications. ISSN 2468-2942. 38, p. 1–8. doi: 10.1016/j.ctarc.2023.100785.
  • Huynh, Thuy-Tien Maria; Dale, Einar; Falk, Ragnhild Sørum; Hellebust, Taran Annette Paulsen; Astrup, Guro Lindviksmoen & Malinen, Eirik [Show all 12 contributors for this article] (2023). Radiation-induced long-term dysphagia in survivors of head and neck cancer and association with dose-volume parameters. Radiotherapy and Oncology. ISSN 0167-8140. 190. doi: 10.1016/j.radonc.2023.110044. Full text in Research Archive
  • Nilssen, Yngvar; Solberg, Steinar; Brustugun, Odd Terje; Møller, Bjørn; Sundset, Arve & Wahl, Sissel Gyrid Freim [Show all 7 contributors for this article] (2023). Tracheal cancer: a rare and deadly but potentially curable disease that also affects younger people. European Journal of Cardio-Thoracic Surgery. ISSN 1010-7940. 64(1). doi: 10.1093/ejcts/ezad244. Full text in Research Archive
  • Levi, Hagai; Carmi, Shai; Rosset, Saharon; Yerushalmi, Rinat; Zick, Aviad & Yablonski-Peretz, Tamar [Show all 155 contributors for this article] (2023). Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel. Journal of Medical Genetics. ISSN 0022-2593. 60(12), p. 1186–1197. doi: 10.1136/jmg-2023-109185. Full text in Research Archive
  • Børø, Siri; Thoresen, Steinar; Boge Brant, Simon & Helland, Åslaug (2023). Initial investigation of using Norwegian health data for the purpose of external comparator arms - an example for non-small cell lung cancer. Acta Oncologica. ISSN 0284-186X. p. 1–7. doi: 10.1080/0284186X.2023.2264484. Full text in Research Archive
  • Le Tourneau, Christophe; André, Fabrice; Helland, Åslaug; Mileshkin, Linda; Minnaard, Warnyta & Schiel, Anja [Show all 14 contributors for this article] (2023). Modified study designs to expand treatment options in personalised oncology: a multistakeholder view. European Journal of Cancer. ISSN 0959-8049. 194. doi: 10.1016/j.ejca.2023.113278. Full text in Research Archive
  • Figlioli, Gisella; Billaud, Amandine; Wang, Qin; Bolla, Manjeet K.; Dennis, Joe & Lush, Michael [Show all 96 contributors for this article] (2023). Spectrum and Frequency of Germline FANCM Protein-Truncating Variants in 44,803 European Female Breast Cancer Cases. Cancers. ISSN 2072-6694. 15(13). doi: 10.3390/cancers15133313. Full text in Research Archive
  • Langberg, Christian Wilhelm; Horndalsveen, Henrik; Helland, Åslaug & Haakensen, Vilde Drageset (2023). Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC. Frontiers in Oncology. ISSN 2234-943X. 13, p. 1–11. doi: 10.3389/fonc.2023.1217424. Full text in Research Archive
  • Rakaee, Mehrdad; Andersen, Sigve; Giannikou, K.; Paulsen, Erna-Elise; Kilvær, Thomas Karsten & Busund, Lill-Tove Rasmussen [Show all 25 contributors for this article] (2023). Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial. Annals of Oncology. ISSN 0923-7534. doi: 10.1016/j.annonc.2023.04.005. Full text in Research Archive
  • Mueller, Stefanie H.; Lai, Alvina G.; Valkovskaya, Maria; Michailidou, Kyriaki; Bolla, Manjeet K. & Wang, Qin [Show all 207 contributors for this article] (2023). Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry. Genome Medicine. ISSN 1756-994X. 15(7). doi: 10.1186/s13073-022-01152-5. Full text in Research Archive
  • Ottesen, Jon André; Yi, Darvin; Tong, Elizabeth; Iv, Michael; Latysheva, Anna & Saxhaug, Cathrine [Show all 13 contributors for this article] (2023). 2.5D and 3D segmentation of brain metastases with deep learning on multinational MRI data. Frontiers in Neuroinformatics. ISSN 1662-5196. 16, p. 1–12. doi: 10.3389/fninf.2022.1056068. Full text in Research Archive
  • Chen, Jiajin; Song, Yunjie; Li, Yi; Wei, Yongyue; Shen, Sipeng & Zhao, Yang [Show all 18 contributors for this article] (2022). A trans-omics assessment of gene–gene interaction in early-stage NSCLC. Molecular Oncology. ISSN 1574-7891. p. 1–15. doi: 10.1002/1878-0261.13345. Full text in Research Archive
  • Børø, Siri; Thoresen, Steinar Østerbø & Helland, Åslaug (2022). Improvements in survival for patients with stage IV adenocarcinoma in the lung, diagnosed between 2010 – 2020 - A population-based registry study from Norway. Frontiers in Oncology. ISSN 2234-943X. 12. doi: 10.3389/fonc.2022.1017902.
  • Maggadottir, Solrun Melkorka; Kvalheim, Gunnar; Wernhoff, Patrik; Sæbøe-Larssen, Stein; Rootwelt-Revheim, Mona Elisabeth & Josefsen, Dag [Show all 9 contributors for this article] (2022). A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT). Frontiers in Oncology. ISSN 2234-943X. 12, p. 1–14. doi: 10.3389/fonc.2022.1031232. Full text in Research Archive
  • Dixon-Suen, Suzanne C.; Lewis, Sarah; Martin, Richard M.; English, Dallas R.; Boyle, Terry & Giles, Graham G. [Show all 174 contributors for this article] (2022). Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study. British Journal of Sports Medicine. ISSN 0306-3674. 56(20), p. 1157–1170. doi: 10.1136/bjsports-2021-105132.
  • Huynh, Thuy-Tien Maria; Aass, Hans Christian Dalsbotten; Falk, Ragnhild Sørum; Astrup, Guro Lindviksmoen; Helland, Åslaug & Bjøro, Trine [Show all 14 contributors for this article] (2022). Associations between patient-reported late effects and systemic cytokines in long-term survivors of head and neck cancer treated with radiotherapy. Journal of cancer survivorship. ISSN 1932-2259. doi: 10.1007/s11764-022-01273-1. Full text in Research Archive
  • Horndalsveen, Henrik; Alver, Tine Norman; Dalsgaard, Astrid Marie; ROGG, LOTTE VICTORIA; Helbekkmo, Nina & Grønberg, Bjørn Henning [Show all 12 contributors for this article] (2022). Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT-1 trial. Molecular Oncology. ISSN 1574-7891. doi: 10.1002/1878-0261.13330. Full text in Research Archive
  • Helland, Åslaug; Andersen, Klaus Kaae; Myklebust, Tor Åge; Johannessen, Tom Børge; Aarøe, Jørgen Mømb & Enerly, Espen (2022). EGFR-mutation testing and TKI treatment patterns in locally advanced and metastatic NSCLC in Norway – A nationwide retrospective cohort study. Cancer Treatment and Research Communications. ISSN 2468-2942. 33, p. 1–7. doi: 10.1016/j.ctarc.2022.100636.
  • Eide, Inger Johanne; Stensgaard, Simone; Helland, Åslaug; Ekman, Simon; Mellemgaard, Anders & Hansen, Karin Holmskov [Show all 11 contributors for this article] (2022). Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials. Translational Lung Cancer Research (TLCR). ISSN 2218-6751. 11(6), p. 953–963. doi: 10.21037/tlcr-21-995. Full text in Research Archive
  • Khadse, Anand; Haakensen, Vilde Drageset; Silwal-Pandit, Laxmi; Hamfjord, Julian; Micke, Patrick & Botling, Johan [Show all 10 contributors for this article] (2022). Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma. Frontiers in Oncology. ISSN 2234-943X. 12. doi: 10.3389/fonc.2022.873532.
  • Solberg, Steinar; Nilssen, Yngvar; Brustugun, Odd Terje; Haram, Per Magnus; Helland, Åslaug & Møller, Bjørn [Show all 9 contributors for this article] (2022). Concordance between clinical and pathology TNM-staging in lung cancer. Lung Cancer. ISSN 0169-5002. 171, p. 65–69. doi: 10.1016/j.lungcan.2022.07.014. Full text in Research Archive

View all works in Cristin

  • Ringborg, Ulrik; von Braun, Joachim; Celis, Julio; Baumann, Michael; Berns, Anton & Eggermont, Alexander [Show all 37 contributors for this article] (2023). Strategies to decrease inequalities in cancer therapeutics, care and prevention: Proceedings on a conference organized by the Pontifical Academy of Sciences and the European Academy of Cancer Sciences, Vatican City, February 23–24, 2023. Molecular Oncology. ISSN 1574-7891. doi: 10.1002/1878-0261.13575. Full text in Research Archive
  • Helland, Åslaug (2023). Plenumsforedrag: Kong Olav Vs kreftforskinngspris 2023 .
  • Helland, Åslaug (2023). Care quality in lung cancer - the dinastry protocol .
  • Helland, Åslaug (2023). Presisjonsmedisin innen lungekreft .
  • Helland, Åslaug (2023). NIPU studien og mesoteliom .
  • Ukjent, Person & Helland, Åslaug (2023). NIPU results at ESMO (Webcast). [Internet]. Hegnar Media.
  • Helland, Åslaug (2023). NIPU - first data on survival in the NIPU trial (oral presentation, late breaking abstract) .
  • Helland, Åslaug (2023). Norway as a clinical trial destination.
  • Helland, Åslaug (2023). Digicore: et system for samling og bruk av virkelighetsdata .
  • Helland, Åslaug (2023). IMPRESS-Norway: set-up and status.
  • Helland, Åslaug (2023). Investigator-initiated studies in radiotherapy - possibilities and challenges.
  • Helland, Åslaug (2023). Integrering av kliniske studier i pasientbehandlingen.
  • Helland, Åslaug (2023). IMPRESS-Norway - erfaringer etter to års aktivitet. Tidsskrift for kreftsykepleiere.
  • Helland, Åslaug (2023). OUS arrangement: nye sykehus - nytt Radiumhospital. .
  • Helland, Åslaug (2023). NYE LEGEMIDLER: HVORDAN GJØR VI DE VANSKELIGE PRIORITERINGENE?
  • Helland, Åslaug (2023). Experiences from the IMPRESS-Norway trial - implementing precision cancer medicine in Norway (keynote talk).
  • Helland, Åslaug (2023). Panel debate about molecular diagnostics.
  • Helland, Åslaug (2023). Implementation of precison cancer medicine.
  • Kjørstad, Elise & Helland, Åslaug (2023). Lungekreft-pille halverte risikoen for å dø. [Business/trade/industry journal]. Forskning.no.
  • Helland, Åslaug (2023). Forskningspresentasjoner av nye DNVA medlemmer - Åslaug Helland.
  • Helland, Åslaug (2023). Oppdatering om presisjonsmedisin.
  • Helland, Åslaug (2023). Presisjonskreftmedisin.
  • Helland, Åslaug (2023). IMPRESS-Norway status.
  • Helland, Åslaug (2023). Fremtidens presisjonsmedisin; molekylærbiologens perspektiv.
  • Rolland, Øyvind; Andersen, Sigve; Aagnes, Stian & Helland, Åslaug (2023). Stian har livstruende lungekreft: – Jeg er beviset på at forskning nytter. [Business/trade/industry journal]. Forskning.no.
  • Helland, Åslaug (2023). Structuring sharing of infrastructures and patients for precision cancer medicine clinical trials in Norway.
  • Helland, Åslaug (2023). Precision Cancer Medicine - IMPRESS-Norway and MATRIX.
  • Ukjent, Person & Helland, Åslaug (2023). IMPRESS-Norway og MATRIX. [Internet]. Helse Møre og Romsdal HF, årsrapport.
  • Helland, Åslaug (2023). IMPRESS-Norway, MATRIX, NorTrials - presisjonsmedisin-aktiviteter i Norge (møte med Astra Zeneca).
  • Helland, Åslaug (2023). Private-public partnerships.
  • Helland, Åslaug (2023). National engagement in precision cancer medidine.
  • Helland, Åslaug (2023). PCM4EU kick-off presentation: WP3.
  • Helland, Åslaug (2023). Kreftgåten.
  • Heia, Ingvild; Tasken, Kjetil; Helland, Åslaug; Russnes, Hege Elisabeth Giercksky & Smeland, Sigbjørn (2023). Innføring av presisjonsmedisin innen kreft i Norge. [Newspaper]. Aftenposten (Innstikk «Persontilpasset behandling).
  • Bjørgo, elisa; Tasken, Kjetil & Helland, Åslaug (2023). PRIME-ROSE: Millionstøtte til OUS-ledet EU-prosjekt innen persontilpasset kreftbehandling. [Internet]. Oslo Universitetssykehus.
  • Bjørgo, Elisa; Fagereng, Gro Live; Russnes, Hege Elisabeth Giercksky; Smeland, Sigbjørn; Tasken, Kjetil & Helland, Åslaug (2023). ACTA Oncologica Nordic Precision Cancer Medicine Symposium 2023 – Merging Clinical Research and Standard Healthcare. Acta Oncologica. ISSN 0284-186X.
  • Nilsen, Lars Broch & Helland, Åslaug (2023). Helland om utviklingen av lungekreft-behandling: – Flere pasienter vi nå kan gjøre mye for. [Business/trade/industry journal]. Health Talk.
  • Helland, Åslaug (2023). ESMO 2023 Lung Cancer – Åslaug Helland. Magazine of European Medical Oncology (memo).
  • Helland, Åslaug; Einarsson, Einar; Andersen, Elisabeth Kirkeng & Bjørheim, Jens (2023). Podkastserien Radium, Episode 286: NIPU-dataene med Åslaug Helland og Jens Bjørheim. [Internet]. Podcast.
  • Vebenstad, Marit Aaby; Helland, Åslaug; Grønberg, Bjørn Henning & Moksnes, Maria (2023). Resultater fra CheckMate 77T gir stor entusiasme i lungekreftmiljøet. [Business/trade/industry journal]. Onkologisk Tidsskrift.
  • Vebenstad, Marit Aaby; Helland, Åslaug; Grønberg, Bjørn Henning & Bjaanes, Maria Moksnes (2023). Rybrevant pluss kjemoterapi gir overbevisende resultater i NSCLC med exon20-mutasjon. [Business/trade/industry journal]. Onkologisk Tidsskrift.
  • Anderssen, Hans & Helland, Åslaug (2023). Ultimovacs: Åslaug Helland svarer på kritikk mot NIPU-studien på ESMO i Madrid. [Internet]. Health Talk.
  • Anderssen, Hans & Helland, Åslaug (2023). Pasienter med brysthinnekreft lever 4,3 måneder lenger med kreftvaksinen til Ultimovacs. [Internet]. Health Talk.
  • ONDRČKOVA, Camilla Øvrebø; Helland, Åslaug; Blix, Egil Støre; Heinrich, Daniel & Lindemann, Kristina Yvonne Kathe (2023). ESMO-kongressen 2023 – dette gleder kreftlegene seg til. [Newspaper]. Dagens Medisin.
  • ONDRČKOVA, Camilla Øvrebø & Helland, Åslaug (2023). NIPU-studien: Signifikant forbedring i overlevelse med UV1-kreftvaksine. [Newspaper]. Dagens Medisin.
  • Anderssen, Hans & Helland, Åslaug (2023). Ultimovacs kraftig opp på børsen etter nyhet om kreftstudie. [Internet]. Health Talk.
  • Vebenstad, Marit Aaby; Rootwelt, Terje & Helland, Åslaug (2023). Administrerende direktør i Helse Sør-Øst: Internasjonalt samarbeid om presisjonsmedisin er viktig. [Business/trade/industry journal]. Onkologitidsskrift.no.
  • Vebenstad, Marit Aaby; Helland, Åslaug & Rootwelt, Terje (2023). Leder av Beslutningsforum: Vi har mye å lære av det danske Medicinrådet. [Business/trade/industry journal]. Onkologitidsskrift.no.
  • Simonsen, Michael Chr. A. & Helland, Åslaug (2023). Aksjekursen til selskapet falt med rundt 30 prosent torsdag formiddag. Åslaug Helland, hovedutprøver for studien, er likevel positiv. [Business/trade/industry journal]. Dagens Medisin.
  • Henmo, Ola; Helland, Åslaug; Mala, Tom; Verbeke, Caroline Sophie & Bjerkvig, Rolf (2023). Dette superteamet skal løse våre største kreftutfordringer. [Business/trade/industry journal]. Forskning.no.
  • Anderssen, Hans & Helland, Åslaug (2023). Åslaug Helland om osimertinib etter operasjon: – En åpenbar fordel. [Internet]. Health Talk.
  • Nilsen, Lars Broch & Helland, Åslaug (2023). Åslaug Helland om Keynote-studie på lungekreft: – Kjempeviktig for pasientene. [Internet]. Health Talk.
  • Lindeberg, Stella O & Helland, Åslaug (2023). Sogn-beboer Åslaug Helland (56) fikk tirsdag ettermiddag Kong Olav Vs Kreftforeningspris 2023. Den ble overrakt av selveste Kong Harald. [Newspaper]. Nordre Aker Budstikke.
  • NRK, Dagsrevyen TV & Helland, Åslaug (2023). Innslag i Dagsrevyen fra utdelinge av Kreftforskningsprisen 2023. [TV]. NRK Dagsrevyen.
  • Kreftforeningen, Journalist & Helland, Åslaug (2023). Kong Harald hedret Helland. [Internet]. Kreftforeningens .
  • TV2, Nyhetskanalen & Helland, Åslaug (2023). TV2 Nyhetskanalen - intervju med prisvinner kreftforskningsprisen. [TV]. TV2 Nyhetskanalen.
  • Dahl, Anders N & Helland, Åslaug (2023). Selveste Kong Harald skal dele ut prisen den 2. mai. Se video av da hun fikk beskjed om at hun vant. [Internet]. Østlandets Blad.
  • Anderssen, Hans & Helland, Åslaug (2023). Åslaug Helland hedres med Kong Olav Vs kreftforskningspris. [Internet]. Health Talk.
  • NRK, nyhetsjournalist; Helland, Åslaug & Grønås, Kari (2023). NRK Nyhtesmorgen - intervju om Kong Olav Vs kreftforskningspris 2023. [Radio]. NRK.
  • Dommerud, Tine; Helland, Åslaug & Grønås, Kari (2023). Kreften hadde spredt seg overalt i kroppen. Men Kari Grønås ble ikke gitt opp av legen sin. [Newspaper]. Aftenposten.
  • Nilsen, Lars Broch & Helland, Åslaug (2023). To år med Impress: Dette er nøkkeltallene fra den nasjonale kliniske kreftstudien. [Internet]. Health Talk.
  • Simonsen, Michael Chr. A. & Helland, Åslaug (2023). IMPRESS-studien er to år: – Har løftet kompetansen hos både onkologer og diagnostikere i hele Norge. [Internet]. Dagens Medisin.
  • Anderssen, Hans & Helland, Åslaug (2023). Åslaug Helland valgt inn i vitenskapsakademi: – En anerkjennelse. [Internet]. Health Talk.
  • Arnesen, Mats & Helland, Åslaug (2023). Valgte inn nye medlemmer til Videnskaps-Akademiet. [Internet]. Khrono.
  • Heia, Ingvild & Helland, Åslaug (2023). Store fremskritt i behandling av lungekreft. [Internet]. Mediaplanet: Kampanjen Sammen mot kreft.
  • Yi, Darvin; Grøvik, Endre; Tong, Elizabeth; Iv, Michael; Emblem, Kyrre E & Nilsen, Line [Show all 12 contributors for this article] (2023). Erratum to: MRI pulse sequence integration for deep-learning-based brain metastases segmentation (Medical Physics, (2021), 48, 10, (6020-6035), 10.1002/mp.15136). Medical Physics (Lancaster). ISSN 0094-2405. 50(8). doi: 10.1002/mp.16594.
  • Skoie, Inger Marie; Skogås, Jan Gunnar; Langø, Thomas; Myhr, Kjell-Morten; Myhre, Peder Langeland & Goll, Rasmus [Show all 8 contributors for this article] (2023). Nye sentre skal gi flere kliniske studier i Norge. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 143(2). doi: 10.4045/tidsskr.22.0722. Full text in Research Archive
  • Berg, Janna; Halvorsen, Ann Rita; Bengtson, May-Bente; Lindberg, Morten; Halvorsen, Bente & Aukrust, Pål [Show all 8 contributors for this article] (2022). Corrigendum: Circulating T cell activation and exhaustion markers are associated with radiation pneumonitis and poor survival in non-small-cell lung cancer, (Front. Immunol, (2022), 13, (875152), 10.3389/fimmu.2022.875152). Frontiers in Immunology. ISSN 1664-3224. 13. doi: 10.3389/fimmu.2022.1051156.
  • Kalveland, Julie; Helland, Åslaug & Frich, Jan C (2022). Jubler over at staten tar regningen for ny behandling. [Newspaper]. Dagens Medisin.
  • Helland, Åslaug (2022). Åslaug Helland om siste nytt fra ESMO og mye annet. [Internet]. Radium Podcast, Episode 244.
  • Helland, Åslaug (2022). Intervju med Åslaug Helland om presisjonsmedisin, Matrix mm. [Internet]. Radium Podcast.
  • Kaalstad, Jørn E. & Helland, Åslaug (2022). Stor norsk studie: Nytt håp for oppgitte kreftpasienter. [Newspaper]. VG.
  • Kaalstad, Jørn E. & Helland, Åslaug (2022). Alvorlig syke kreftpasienter får medisiner: Staten tar regningen. [Newspaper]. VG.
  • Tasken, Kjetil; Helland, Åslaug; Russnes, Hege Elisabeth Giercksky; Smeland, Sigbjørn; Frich, Jan C. & Thoresen, Steinar [Show all 13 contributors for this article] (2022). Arendalsuka 2022: Nøkkelen til bedre kreftbehandling er samarbeid. [Internet]. Arendalsuka, Paneldebatt.
  • Helland, Åslaug (2022). Store utfordringer og enorme muligheter innen kreftbehandling med Åslaug Helland. [Internet]. Abbvie Podcast, Utvid horisonten, episode 18.
  • Engsig, Michael; Tasken, Kjetil; Grodt Schmidt, Jannik & Helland, Åslaug (2022). Norway’s precision medicine takes aim at cancer. [Journal]. The Explorer.
  • Tasken, Kjetil; Russnes, Hege Elisabeth Giercksky; Aas, Eline; Bjørge, Line; Blix, Egil Støre & Ahlquist, Terje C. [Show all 116 contributors for this article] (2022). A national precision cancer medicine implementation initiative for Norway. Nature Medicine. ISSN 1078-8956. 28(5), p. 885–887. doi: 10.1038/s41591-022-01777-4.
  • Helland, Åslaug; Russnes, Hege Elisabeth Giercksky; Fagereng, Gro Live; Al-Shibli, Khalid Ibrahim; Andersson, Yvonne & Berg, Thomas [Show all 53 contributors for this article] (2022). Correction to: Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway (Journal of Translational Medicine, (2022), 20, 1, (225), 10.1186/s12967-022-03432-5). Journal of Translational Medicine. ISSN 1479-5876. 20(1). doi: 10.1186/s12967-022-03518-0.

View all works in Cristin

Published Sep. 23, 2016 12:16 PM - Last modified Sep. 14, 2017 1:25 PM